InflaRx (IFRX +12.7%) jumps on a 5x surge in volume in apparent reaction to results from the first portion of a Phase 2/3 clinical trial, PANAMO, in the Netherlands evaluating lead candide IFX-1 plus best supportive care (BSC) in severely ill hospitalized adult COVID-19 patients. The data were just published in The Lancet Rheumatology.
Patients receiving IFX-1 plus BSC experienced a 24% relative improvement in blood oxygenation, measured by the mean PaO2/FiO2 ratio (arterial oxygen partial pressure/fractional inspired oxygen), versus BSC and a 14% relative mortality benefit at day 28.
The safety profiles were similar.
The Phase 3 portion launched two weeks ago.
In June, shares briefly sold off on preliminary data that showed no difference in between IFX-1 and BSC in the oxygenation index.
IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to induce an anti-inflammatory response by blocking the biological activity of C5a.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.